DLBCL: Management of Primary Refractory and Relapsed/Refractory Disease

Source: Aggressive B-Cell Lymphomas: Experts Discuss New Care Standards and Evolving Treatment Strategies
Download Slideset
Download these slides from a live symposium at ASH 2022 to gain more insight into the optimal management of primary refractory and relapsed/refractory DLBCL.
John Allan, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 722 KB
Released: December 12, 2022

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Genmab US, Inc. and AbbVie
Karyopharm Therapeutics Inc.
Regeneron Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings